ANI Pharma (ANIP) Tops Q1 EPS by 36c ; Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.70, $0.36 better than the analyst estimate of $1.34. Revenue for the quarter came in at $197.1 million versus the consensus estimate of $179.21 million.

GUIDANCE:

ANI Pharma sees FY2025 EPS of $6.27-$6.62, versus the consensus of $6.34. ANI Pharma sees FY2025 revenue of $768-793 million, versus the consensus of $769.6 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Sandisk targets mid-to-high teens revenue growth through FY2030
• Cantor Fitzgerald Reiterates Overweight Rating on Global Net Lease (GNL)
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c